Trust Point Inc. Has $654,000 Stock Position in Enovis Co. (NYSE:ENOV)

Trust Point Inc. reduced its position in shares of Enovis Co. (NYSE:ENOV) by 6.8% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 14,903 shares of the company’s stock after selling 1,083 shares during the quarter. Trust Point Inc.’s holdings in Enovis were worth $654,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of the business. Confluence Investment Management LLC acquired a new position in Enovis in the fourth quarter valued at approximately $3,494,000. Chartwell Investment Partners LLC lifted its stake in shares of Enovis by 25.6% in the 3rd quarter. Chartwell Investment Partners LLC now owns 201,652 shares of the company’s stock valued at $8,681,000 after purchasing an additional 41,089 shares during the period. Geode Capital Management LLC boosted its position in shares of Enovis by 9.5% in the 3rd quarter. Geode Capital Management LLC now owns 921,437 shares of the company’s stock worth $39,678,000 after purchasing an additional 80,165 shares during the last quarter. UMB Bank n.a. grew its stake in shares of Enovis by 128.2% during the fourth quarter. UMB Bank n.a. now owns 778 shares of the company’s stock worth $34,000 after purchasing an additional 437 shares during the period. Finally, Dynamic Technology Lab Private Ltd bought a new stake in Enovis in the third quarter valued at about $1,050,000. Institutional investors own 98.45% of the company’s stock.

Enovis Stock Performance

Shares of Enovis stock opened at $46.14 on Wednesday. Enovis Co. has a 12 month low of $38.27 and a 12 month high of $65.03. The company has a current ratio of 2.27, a quick ratio of 1.12 and a debt-to-equity ratio of 0.40. The company has a market capitalization of $2.62 billion, a PE ratio of -21.07 and a beta of 1.94. The stock’s fifty day simple moving average is $46.01 and its 200 day simple moving average is $44.50.

Enovis (NYSE:ENOV) last released its quarterly earnings data on Wednesday, November 6th. The company reported $0.73 earnings per share for the quarter, beating the consensus estimate of $0.62 by $0.11. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. The business had revenue of $505.22 million for the quarter, compared to analysts’ expectations of $504.44 million. During the same quarter in the previous year, the business posted $0.56 EPS. Enovis’s revenue for the quarter was up 21.0% on a year-over-year basis. On average, research analysts predict that Enovis Co. will post 2.79 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, Needham & Company LLC restated a “buy” rating and set a $65.00 target price on shares of Enovis in a report on Thursday, November 7th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $65.86.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.